Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H22ClN3O2 |
Molecular Weight | 407.893 |
Optical Activity | ( + ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCC(=O)C[C@@H]1N(C(=O)C2=CC=CC=C12)C3=CC=C4C=CC(Cl)=NC4=N3
InChI
InChIKey=HIUPRQPBWVEQJJ-IBGZPJMESA-N
InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3/t19-/m0/s1
Molecular Formula | C23H22ClN3O2 |
Molecular Weight | 407.893 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15926867Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB04903 |
https://www.ncbi.nlm.nih.gov/pubmed/?term=18728798
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15926867
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB04903 |
https://www.ncbi.nlm.nih.gov/pubmed/?term=18728798
Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopiclone. It binds with the roughly equivalent high affinity (0.7–9.1 nM) to the benzodiazepine binding site of human GABAA receptors containing either a α1, α2, α3 or α5 subunit. It is a partial agonist at α1-, α2- and α5-containing GABAA receptors and a full agonist at receptors containing a α3 subunit. Pagoclone produces anxiolytic effects with little sedative or amnestic actions at low doses.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=16430927
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/?term=22204486
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12871032 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. | 2001 Sep |
|
Psychopharmacology of anxiety disorders. | 2002 Sep |
|
Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. | 2003 Aug |
|
Pagoclone Indevus. | 2003 Jan |
|
Gateways to clinical trials. | 2004 Apr |
|
A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. | 2005 Aug |
|
The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. | 2005 May |
|
Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. | 2006 Jun |
|
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone. | 2006 May |
|
Gateways to clinical trials. | 2007 Mar |
|
Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance. | 2008 Feb |
|
Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pagoclone for peRsistent dEvelopmental Stuttering Study. | 2010 Feb |
|
Gateways to clinical trials. | 2010 Jun |
|
Comments on article by Maguire et al: pagoclone trial: questionable findings for stuttering treatment. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=18728798
Subjects received 0.15 mg (low), 0.30 mg (medium), or 0.60 mg (high) oral doses of pagoclone every 12 hours for seven days with a seven-day washout between periods.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12871032
Pagoclone binds with roughly equivalent high affinity (0.7–9.1 nM) to the benzodiazepine binding site of human GABAA receptors containing either an α1, α2, α3 or α5 subunit.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:47:13 GMT 2023
by
admin
on
Fri Dec 15 16:47:13 GMT 2023
|
Record UNII |
38VAG2SA33
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
133737-32-3
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
ALTERNATIVE | |||
|
DB04903
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
38VAG2SA33
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
GG-84
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
131664
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
SUB09586MIG
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
7400
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
133737-48-1
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
m8354
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000082759
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104745
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
Pagoclone
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
C74529
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
1515959-69-9
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY | |||
|
DTXSID40869830
Created by
admin on Fri Dec 15 16:47:13 GMT 2023 , Edited by admin on Fri Dec 15 16:47:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
The major metabolite of pagoclone, 5′-hydroxy pagoclone, was present at 10–20-fold higher concentrations relative to the parent compound.
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
BINDING
Ki
|